Table 1 |
|
|
Patient characteristics, disease-modifying antirheumatic drug (DMARD) use, and biomarker concentrations 1 year after diagnosis |
|
| Age (years) |
58 ± 13 |
| Gender, women (%) |
63 |
| Rheumatoid factor, positive (%) |
68 |
| Erythrocyte sedimentation rate (mm/h1st) |
25 ± 25 |
| Joint score, Thompson |
52 ± 77 |
| Morning stiffness (min) |
44 ± 88 |
| Visual analogue scale pain (mm) |
24 ± 25 |
| Visual analogue scale general well-being (mm) |
31 ± 26 |
| Functional disability score, Health Assessment Questionnaire |
0.96 ± 0.70 |
| Radiographic damage, erosions |
7.2 ± 8.3 |
| Radiographic damage, narrowing |
3.7 ± 4.1 |
| Total radiographic damage score, Sharp/van der Heijde |
10.9 ± 11.2 |
| DMARD use [number (%)] |
|
| No DMARD |
6 (7) |
| Intramuscular gold |
19 (22) |
| Methotrexate |
26 (30) |
| Hydroxychloroquine |
21 (24) |
| D-penicillamine |
7 (8) |
| Sulfasalazine |
4 (5) |
| Imuran |
1 (1) |
| Auranofin |
3 (3) |
| Biomarker concentrations |
|
| C2C (ng/ml) |
130 ± 62 |
| C1,2C (ng/ml) |
514 ± 287 |
| CS846-epitope (ng/ml) |
61 ± 22 |
| CPII (ng/ml) |
242 ± 180 |
|
|
|
|
Values presented as the mean ± standard deviation for continuous variables and percentages for categorical variables. Rheumatoid factor positive, patients testing positive either at diagnosis or 1 year. C2C, a marker for degradation of type II collagen in cartilage; C1,2C, a marker for degradation of type I and type II collagen in cartilage; CS846-epitope, a marker for aggrecan turnover in cartilage; CPII, a marker for synthesis of the pro-collagen of type II collagen cartilage. |
|
|
Verstappen et al. Arthritis Research & Therapy 2006 8:R31 doi:10.1186/ar1882 |
|
